Can I get it?
Yes, if a doctor decides it is right for you. Tirzepatide is authorised in the EU and can be prescribed after a medical review.
TirzepatidePrescription only
Online medical consultation for Tirzepatide.
An EU-licensed doctor reviews your case and, if eligible, issues an electronic prescription valid at any EU pharmacy under Directive 2011/24/EU.
- Once-weekly pen
- Dual GIP/GLP-1 receptor action
- Doctor-supervised, step-wise escalation
Start consultationStart consultation · €25/month
Full refund if a review is not approved · Medication, if prescribed, is dispensed and paid for separately at a pharmacy.
IN PLAIN TERMS
What Tirzepatide is, and how to get treatment
Tirzepatide is a medicine given as an injection under the skin once a week. It acts on two natural gut-hormone signals at once, GLP-1 and GIP, which together lower appetite and slow how fast food leaves the stomach, so people usually eat less. In the EU it is sold as Mounjaro. It was first authorised in September 2022 for type 2 diabetes, and its licence was extended on 11 December 2023 to cover weight management alongside a reduced-calorie diet and more physical activity.
Tirzepatide has been authorised for use in the EU since 11 December 2023, so a licensed doctor can prescribe it when it is clinically appropriate for you.
Learn more about peptides at Peptidepedia.
What can I take instead?
Our doctors review every Weight loss option and recommend what fits your history and goals.
See all Weight loss optionsWhat do the studies show?
Every trial behind Tirzepatide is listed below with its registry number, how many people took part, and whether the results are peer-reviewed or a company announcement.
Jump to the studiesVERIFIED EVIDENCE
Tirzepatide: evidence and regulatory guide.
WHAT IT IS
How it works
It switches on two gut-hormone receptors at the same time, GIP and GLP-1, which together reduce appetite and slow how quickly the stomach empties.
- GIP
- GLP-1
DEVELOPMENT STAGE
EU-authorised medicine
Trial register1 registered trials
Every NCT identifier links to its ClinicalTrials.gov record. A readout is not the same as peer-reviewed publication.
| TRIAL / NCT | POPULATION | PARTICIPANTS | STATUS | READOUT / COMPLETION |
|---|---|---|---|---|
| SURMOUNT-1NCT04184622 | Adults with a BMI of 30 kg/m² or more, or 27 kg/m² or more with at least one weight-related complication, without type 2 diabetes; all received diet and exercise counselling | 2,539 | Read out | 2022-07-21 |
What the studies reported
Results are grouped by source and evidence grade so journal data and manufacturer announcements cannot be confused.
Peer-reviewed
Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038 (PMID 35658024)| DOSE OR GROUP | MEAN WEIGHT CHANGE | WEEKS |
|---|---|---|
| 5 mg once weekly | −15.0% | 72 |
| 10 mg once weekly | −19.5% | 72 |
| 15 mg once weekly | −20.9% | 72 |
| Placebo | −3.1% | 72 |
Figures are the treatment-regimen estimand at week 72; people with type 2 diabetes were excluded, everyone also received diet and exercise counselling, and the trial did not follow weight after treatment stopped.
Sources
Last reviewed 2026-07-27
- EMA EPAR — Mounjaro (tirzepatide)
- EMA — Mounjaro procedural steps after authorisation (variation II/0007, extension of indication to chronic weight management; CHMP opinion 09/11/2023, Commission Decision 11/12/2023)
- EMA variation assessment report — Mounjaro II/0007 (EMA/539700/2023)
- SURMOUNT-1 — N Engl J Med 2022;387(3):205-216
- ClinicalTrials.gov — NCT04184622 (SURMOUNT-1)
- ClinicalTrials.gov · NCT04184622
NAMED SAFETY SIGNALS
What has been reported with Tirzepatide.
Nausea
In SURMOUNT-1, reported by 24.6% (5 mg), 33.3% (10 mg) and 31.0% (15 mg) versus 9.5% on placebo.
Diarrhoea
In SURMOUNT-1, reported by 18.7% (5 mg), 21.2% (10 mg) and 23.0% (15 mg) versus 7.3% on placebo.
Constipation
In SURMOUNT-1, reported by 16.8% (5 mg), 17.1% (10 mg) and 11.7% (15 mg) versus 5.8% on placebo.
Vomiting
In SURMOUNT-1, reported by 8.3% (5 mg), 10.7% (10 mg) and 12.2% (15 mg) versus 1.7% on placebo.
Hair thinning
Alopecia was reported by 5.1% (5 mg), 4.9% (10 mg) and 5.7% (15 mg) versus 0.9% on placebo in SURMOUNT-1.
Acute pancreatitis
Independently confirmed in 3 people on tirzepatide and 1 on placebo across the SURMOUNT-1 safety dataset reviewed by the EMA.
Stopping treatment because of side effects
4.3% (5 mg), 7.1% (10 mg) and 6.2% (15 mg) stopped treatment because of side effects versus 2.6% on placebo.
FormPre-filled injection pen
FrequencyOnce a week
ResultsGradual, over months
What you pay Hi-Doctor€25/month (billed €25 every 28 days)
IN 60 SECONDS
Tirzepatide at a glance
- A long-acting GIP and GLP-1 receptor agonist, given as a pre-filled injection pen.
- Adults who meet the BMI criteria for weight management, and type 2 diabetes.
- One injection under the skin, once a week, on the same day each week.
- Nausea and diarrhoea are very common; severe stomach pain can signal pancreatitis.
- Hi-Doctor consultation fee; the medicine is paid separately at a pharmacy
About
What is Tirzepatide?
Also sold as Mounjaro, Zepbound.
Active ingredient: Tirzepatide · Dosages: 2.5 – 15 mg / week
Tirzepatide is a dual receptor agonist — it acts on the GLP-1 and GIP gut-hormone receptors at the same time. In clinical trials this translates into larger average weight loss than mono-agonist GLP-1s in adults with obesity.
It's a chronic treatment for as long as it's beneficial and safe: the doctor reviews your response every 3 months and decides with you whether to continue, adjust or stop. Discontinuation is gradual and paired with a maintenance plan.
HOW IT WORKS
What Tirzepatide does in your body
By activating two receptors at once, tirzepatide reinforces satiety signals, slows stomach emptying and helps regulate the insulin response — so you tend to eat less without counting every calorie.
Copies two gut hormones
Tirzepatide activates the receptors for two natural gut hormones, GIP and GLP-1, which the body releases after eating. The EU product information describes it as a long acting GIP and GLP-1 receptor agonist that binds both receptors with high affinity.
Turns down appetite signals
Both of those receptors also sit in the brain areas that regulate appetite. Clinical studies cited in the product information report that tirzepatide reduces energy intake and appetite by increasing feelings of satiety and fullness, and by decreasing feelings of hunger.
Slows the stomach, steadies glucose
Tirzepatide delays gastric emptying, so food leaves the stomach more slowly after a meal. It also increases insulin release in a glucose dependent way and lowers glucagon. The weight change comes mainly from eating less, and is mostly a loss of fat mass.
How it helps
Three ways it supports weight loss.
Dual action
Works on two gut-hormone receptors (GLP-1 + GIP), not just one.
Reinforces satiety
Hunger eases and fullness lasts longer after smaller meals.
Reviewed quarterly
Your doctor reassesses response and tolerance every 3 months before renewing.
What to expect
A step-wise, supervised escalation.
The dose is escalated step-wise (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg) every 4 weeks while the body adapts. Your doctor sets your exact schedule.
- Weeks 1–4 · 2.5 mg starting dose
- From week 5 · Step up every 4 weeks as tolerated
- Month 4+ · Personalised maintenance dose
- Ongoing · Quarterly medical reviews
Typical escalation
- Weeks 1–42.5 mg / week
- Step-ups (every 4 weeks)5 → 7.5 → 10 → 12.5 mg
- Maximum dose15 mg / week
Your schedule is personal
These are typical steps only. Your doctor adjusts the plan to how you respond and tolerate it — and you can message them at any point.
DAY TO DAY
Taking Tirzepatide day to day
Pick one day each week
Tirzepatide is injected once a week, at any time of day, with or without food. Pick a day that is easy to remember. You can change the day later as long as three days separate two doses.
Store pens in the fridge
Unused pens are kept in a refrigerator between 2 and 8 degrees Celsius, in the original carton so light cannot reach them, and must never be frozen. A pen that has been frozen must not be used.
Check the pen before use
Look at the liquid before you inject. It should be clear and free of particles or discolouration. Discard the pen if you can see anything floating in it, if it looks discoloured, or if it is out of date.
Inject into tummy, thigh or arm
Tirzepatide goes under the skin of the abdomen, the thigh or the upper arm. The back of the upper arm needs another person to do the injection. Read the instructions for use packed with the pen first.
Rotate the spot every week
Injection sites should be rotated with each dose, so the same patch of skin is not used week after week. If you also inject insulin, use a different site for each of the two medicines.
Missed dose: the four day rule
If you remember within four days, inject then and return to your usual schedule. If more than four days have passed, skip that dose and take the next one on the normal day. Never inject two doses to catch up.
Know how long a pen lasts
Single-dose pens and vials may be kept out of the refrigerator for up to 21 cumulative days below 30 degrees Celsius, then discarded. A multi-dose KwikPen holds four weekly doses and is thrown away 30 days after first use.
Keep the diet and activity going
Tirzepatide is licensed as an addition to a reduced-calorie diet and increased physical activity, not as a replacement for them. Every trial result quoted on this page comes from people doing both alongside the weekly injection.
Safety first
Safety, in full.
Tirzepatide is an effective medicine — and like any medicine it carries risks. Your doctor screens for all of this before prescribing. Here's the honest picture, not just reassurance.
Side effects, by how often they happen
Stop and get urgent medical help if
seek medical help immediately
these need urgent attention, whatever the frequency
- Severe, persistent pain in the stomach area, with or without nausea and vomiting, which can signal pancreatitis
- Breathing problems, or rapid swelling of the lips, tongue or throat
- Difficulty swallowing together with a fast heartbeat, which can signal a severe allergic reaction
- Vomiting or diarrhoea so severe or so lasting that you cannot keep fluids down, because dehydration can damage the kidneys
- Pain in the upper right of the tummy with fever, or yellowing of the skin or eyes
- Shakiness, sweating and confusion, if you also take insulin or a sulfonylurea for diabetes
Very common
very common (≥1/10)
more than 1 in 10 people
- Feeling sick (nausea), most often while the dose is being increased
- Diarrhoea, usually mild or moderate, and easing over time
Common
common (≥1/100 to <1/10)
between 1 in 100 and 1 in 10 people
- Vomiting
- Constipation
- Pain in the stomach area (abdomen)
- Indigestion, bloating, burping, wind or acid reflux
- Tiredness, weakness or generally feeling unwell
- Injection site reactions, most often redness and itching
- Dizziness, or low blood pressure
- A faster heart rate
- Hair loss
- Hypersensitivity reactions such as rash and dermatitis
- Raised lipase or amylase on blood tests
Uncommon
uncommon (≥1/1,000 to <1/100)
between 1 in 1,000 and 1 in 100 people
- Gallstones, or inflammation of the gallbladder (cholecystitis)
- Acute pancreatitis, which is inflammation of the pancreas
- Pain at the injection site
- Raised blood calcitonin, seen only on a blood test
- Delayed stomach emptying, listed as uncommon in UK labelling
Rare
rare (≥1/10,000 to <1/1,000)
between 1 in 10,000 and 1 in 1,000 people
- Anaphylactic reaction, a sudden and severe whole-body allergic reaction
- Angioedema, deep swelling under the skin, often of the face or throat
Adults with obesity (BMI ≥30) or with overweight (BMI ≥27) plus at least one weight-related condition.
- Once-weekly self-injection in the thigh, abdomen or upper arm.
- Dose is escalated step-wise (2.5 mg → 5 → 7.5 → 10 → 12.5 → 15 mg) every 4 weeks while the body adapts.
- Combined with diet and physical activity — tirzepatide complements, not replaces, lifestyle change.
WHO SHOULD NOT TAKE IT, AND WHO NEEDS EXTRA CARE
- You have ever had an allergic reaction to tirzepatide or to any other ingredient in the pen.
- You are pregnant or planning a pregnancy. Tirzepatide is not recommended in pregnancy or in women of childbearing potential not using contraception.
- You are breastfeeding. A risk to the infant cannot be excluded, so the prescriber weighs continuing feeding against continuing treatment.
- You have had pancreatitis. Tirzepatide has not been studied in these patients and should be used with caution.
- You have severe gastrointestinal disease, including severe gastroparesis. Tirzepatide has not been studied in this group.
- You have proliferative diabetic retinopathy, diabetic macular oedema, or retinopathy needing acute treatment. Caution and monitoring apply.
- You are under 18 years old. Safety and efficacy for weight management have not been established below that age.
- You have severe kidney impairment, end stage renal disease, or severe liver impairment. Experience is limited, so caution applies.
- You are booked for general anaesthesia or deep sedation. Tell the team you take tirzepatide, because pulmonary aspiration has been reported.
When to seek urgent care
For severe, sudden or unexpected symptoms, call your local emergency number or go to the nearest emergency department. Then let your doctor know through your account chat.
Medicines and substances that interact
| MEDICINE OR SUBSTANCE | WHAT CAN HAPPEN | WHAT THE DOCTOR DOES |
|---|---|---|
| Oral medicines in general | Tirzepatide delays gastric emptying, so tablets can be absorbed more slowly, especially at the start. | Most oral medicines need no dose change. The prescriber reviews your full list. |
| Warfarin, digoxin and other narrow therapeutic index drugs | Absorption can shift when tirzepatide is started or the dose is increased. | The prescriber monitors you more closely at initiation and after each dose increase. |
| Sulfonylureas (for example gliclazide) | Combined use raises the risk of low blood sugar in people with type 2 diabetes. | The prescriber may reduce the sulfonylurea dose and ask for blood glucose self-monitoring. |
| Insulin | Combined use raises hypoglycaemia risk; clinically significant lows occurred in 14 to 19 percent. | The prescriber reduces insulin stepwise and arranges blood glucose self-monitoring. |
| Combined oral contraceptives | A single 5 mg dose reduced ethinylestradiol peak level by 59 percent and delayed it four hours. | EU labelling requires no dose change. UK labelling advises adding a barrier method for four weeks. |
| Paracetamol | A single 5 mg dose halved the paracetamol peak level and delayed it by one hour. | No dose adjustment needed. Overall exposure was unchanged after four consecutive weekly doses. |
| Oral medicines where rapid onset matters | Delayed gastric emptying can postpone the effect of a tablet you need to work quickly. | The prescriber considers timing, a non-oral route, or an alternative medicine. |
Have a doctor review your caseThis is exactly what the doctor screens for before prescribing anything.
Read the full Tirzepatide safety summaryEVIDENCE
What the clinical trials found
The SURMOUNT phase 3 programme tested tirzepatide against placebo for weight management, and reported mean body-weight reductions of 15.0% to 20.9% over 72 weeks depending on the dose.
2,539 adults with obesity or overweight, without diabetes · 72 weeks
SURMOUNT-1. Mean baseline weight 104.8 kg. The placebo group changed -3.1%.
Source: SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity2,539 adults with obesity or overweight, without diabetes · 72 weeks
SURMOUNT-1. 3% of the placebo group reached that threshold. On 15 mg, 91% reached at least 5%.
Source: SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity938 adults with obesity and type 2 diabetes · 72 weeks
SURMOUNT-2. This group sits inside the EU weight-management licence. The placebo group changed -3.2%.
Source: SURMOUNT-2: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes670 adults who completed a 36-week tirzepatide lead-in · 52 weeks, from week 36 to week 88
SURMOUNT-4. Those switched to placebo regained weight over the following year.
Source: SURMOUNT-4: Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity670 adults who completed a 36-week tirzepatide lead-in · 88 weeks from baseline
SURMOUNT-4. The group switched to placebo at week 36 finished at -9.9% from baseline instead.
Source: SURMOUNT-4: Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesityThese figures are group averages from randomised trials, not a prediction for any one person. Some participants lost far more than the average and some lost very little, and everyone in these trials was also following a reduced-calorie diet and increased physical activity alongside the injection. SURMOUNT-4 also shows the effect depends on continuing treatment, because weight came back in the group that was switched to placebo.
ALTERNATIVES
Tirzepatide vs other EU weight-management medicines
| MEDICINE | HOW IT IS TAKEN | HOW OFTEN | TYPICAL DOSE RANGE | EU-AUTHORISED INDICATION | KEY EVIDENCE |
|---|---|---|---|---|---|
| Semaglutide | Weekly injection | Once weekly | 0.25–2.4 mg | Adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with BMI ≥30, or ≥27 to <30 with at least one weight-related comorbidity. | STEP 1: mean -14.9% body weight at 68 weeks versus -2.4% placebo |
| Liraglutide | Daily injection | Once daily | 0.6–3.0 mg | Adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with BMI ≥30, or ≥27 to <30 with at least one weight-related comorbidity. | SCALE: mean 8.4 kg lost at 56 weeks versus 2.8 kg on placebo |
| Orlistat | Oral capsule | With each main meal | 120 mg per main meal | In conjunction with a mildly hypocaloric diet, for obese patients with BMI ≥30, or overweight patients with BMI ≥28 and associated risk factors. | XENDOS: mean 5.8 kg lost at four years versus 3.0 kg on placebo |
Not sure which one fits your case? The doctor reviews your history and tells you.
Start consultation · €25/monthACCESS AND COST
Getting Tirzepatide, and what it costs
Tirzepatide is a prescription-only medicine everywhere in the EU, so no pharmacy can supply it without a valid prescription from a doctor. Who pays varies by country, and in most of them weight management is not covered by the national health system, which means the patient pays the pharmacy directly. The entries for Spain, France, the Netherlands, Portugal, Belgium and Ireland come from the national sources listed below; the rows for Germany, Italy, Austria and Poland record the general position for this indication and are not confirmed against a national decision, so treat the register linked on those rows as the authority.
What you pay Hi-Doctor
€25/month (billed €25 every 28 days)
Answer a few questions and a licensed EU doctor reviews your case in less than 2 hours on average. Refunded in full if it's not right for you.
What the pharmacy charges
Hi-Doctor does not sell, stock or dispense medicines and does not set their price. The medicine is paid for separately at the pharmacy, and the amount depends on the country, the pack size, whether a generic is available and whether your health system covers it. The official national database linked in the table publishes the current authorised price.
| COUNTRY | HOW IT IS SUPPLIED | COVERED BY THE HEALTH SYSTEM? | OFFICIAL SOURCE |
|---|---|---|---|
| Spain | Prescription-only | Not reimbursed for weight management | AEMPS CIMA |
Show the other countries
| Germany | Prescription-only | Not reimbursed for weight management | PharmNet.Bund AMIce |
|---|---|---|---|
| France | Prescription-only, specialist initiation | Restricted, see national criteria | Base de données publique des médicaments |
| Italy | Prescription-only | Not reimbursed for weight management | AIFA Medicinali |
| Netherlands | Prescription-only | Not reimbursed for weight management | CBG-MEB Geneesmiddeleninformatiebank |
| Portugal | Prescription-only | Not reimbursed for weight management | INFARMED Infomed |
| Belgium | Prescription-only | Not reimbursed for weight management | FAGG-AFMPS medicines database |
| Ireland | Prescription-only | Not reimbursed by the HSE for weight loss | HPRA Find a Medicine |
| Austria | Prescription-only | Not reimbursed for weight management | BASG Medikamente Info Austria |
| Poland | Prescription-only | Not reimbursed, patient pays in full | Rejestr Produktów Leczniczych |
PRICING
You only pay if treatment is approved.
€25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth. One-off consultations are €35 for sexual health and €40 for dermatology.
Weight loss
ONGOING PLAN
€25/month
Billed €25 every 28 days · cancel anytime
28-day treatment cycle
For ongoing treatment and doctor-reviewed renewals.
Renewals reviewed by your doctor
Start consultation
Full refund if a review is not approved
WHAT'S INCLUDED
- First consultation included
- Renewals reviewed by your doctor
- Ongoing care with your doctor
- Cancel anytime
Full refund if a review is not approved
If a review is not approved, we refund that period's €25 fee and cancel the plan.
Note: The medication, if the doctor prescribes it, is paid separately at the pharmacy at the price it sets. Hi-Doctor does not sell medications.
HOW THE DOCTOR DECIDES
A licensed doctor reviews your case, not an algorithm
An EU-licensed doctor reads your questionnaire and answers in less than 2 hours on average.
If the doctor decides it is not safe to prescribe, the consultation fee is refunded in full.
Follow-up happens in the private chat inside your account, under GDPR. No WhatsApp, no SMS.
FREQUENTLY ASKED QUESTIONS
Questions about Tirzepatide.
OTHER WEIGHT LOSS TREATMENTS
Explore related treatments.
SOURCES
Where this information comes from
- 01
Mounjaro (tirzepatide): European public assessment report, medicine overview — European Medicines Agency, 2022
- 02
Mounjaro: Annex I Summary of Product Characteristics — European Commission Union Register of Medicinal Products, 2024
- 03
Mounjaro KwikPen 5 mg solution for injection in pre-filled pen: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 04
Mounjaro KwikPen 15 mg solution for injection in pre-filled pen: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 05
Mounjaro KwikPen 5 mg: Patient Information Leaflet — electronic medicines compendium (emc), 2026
- 06
Tirzepatide (Mounjaro): NHS medicines A to Z — NHS, 2026
- 07
SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity — New England Journal of Medicine, 2022
- 08
SURMOUNT-2: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes — The Lancet, 2023
- 09
SURMOUNT-4: Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity — JAMA, 2024
- 10
STEP 1: Once-weekly semaglutide in adults with overweight or obesity — New England Journal of Medicine, 2021
- 11
SCALE Obesity and Prediabetes: a randomized, controlled trial of 3.0 mg of liraglutide in weight management — New England Journal of Medicine, 2015
- 12
XENDOS: XENical in the prevention of Diabetes in Obese Subjects, a 4-year randomised study — Diabetes Care, 2004
- 13
Wegovy 2.4 mg FlexTouch solution for injection: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 14
Saxenda 6 mg/mL solution for injection: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 15
Xenical 120 mg hard capsules: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 16
CIMA: Mounjaro presentations, marketing and prescription status in Spain — AEMPS (Spanish Agency of Medicines and Medical Devices), 2026
- 17
MOUNJARO (tirzépatide), obésité: avis de la Commission de la Transparence — Haute Autorité de Santé, 2025
- 18
Obésité: prise en charge de WEGOVY et MOUNJARO à partir du 15 juin 2026, sous conditions — VIDAL, reporting the arrêté published in the Journal officiel, 2026
- 19
Tirzepatide (Mounjaro): monograph and reimbursement status in Belgium — BCFI / CBIP, Belgian Centre for Pharmacotherapeutic Information, 2024
- 20
Find a Medicine: authorised medicines database — Health Products Regulatory Authority (Ireland), 2026
- 21
Medicijnkosten.nl: medicine reimbursement database — Zorginstituut Nederland, 2026
- 22
INFOMED: base de dados de medicamentos de uso humano — INFARMED (Portugal), 2026
Reviewed by Hi-Doctor's medical team · Last reviewed 2026-07-27 · Next review due 2027-07-27
This page is educational information about a medicine, not a recommendation to take it and not a substitute for a medical consultation. Only a licensed doctor who has reviewed your history can decide whether a treatment is appropriate for you.
Find out if it's right for you
See if Tirzepatide is appropriate for you.
Answer a few questions and a licensed EU doctor reviews your case in less than 2 hours on average. Refunded in full if it's not right for you.